Calidi Biotherapeutics, Inc.
CLDI
Rank in Stocks
#32211
Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused... Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on immuno-oncology, dedicated to developing advanced immunotherapies for various cancers. The company's innovative approach centers on utilizing powerful, allogeneic (donor-derived) stem cells as specialized carriers for anti-tumor agents. This technology is being advanced to address a range of oncological conditions, including aggressive brain tumors (high-grade gliomas) and other solid malignancies. Calidi's proprietary cell-based delivery systems are expertly designed to safeguard, amplify, and boost the therapeutic effects of oncolytic viruses. This strategic delivery method aims to achieve superior treatment efficacy and enhance patient safety. The company's clinical pipeline features two primary candidates: NeuroNova, which employs allogeneic neural stem cells loaded with an oncolytic adenovirus specifically for the treatment of high-grade gliomas; and SuperNova, which utilizes allogeneic adipose-derived mesenchymal stem cells to deliver the tumor-selective CAL1 oncolytic vaccinia virus for advanced metastatic solid tumors. Established in 2014, Calidi Biotherapeutics operates out of San Diego, California.
Share Price
$0.7331
Last synced: 2026-11-09
Market Cap
$1.89M
Change (1 day)
4.71%
Change (1 year)
-49.44%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Calidi Biotherapeutics, Inc. (CLDI)
Category
Healthcare
EPS for Calidi Biotherapeutics, Inc. (CLDI)
EPS as of June 2026 TTM: $-54.14
According to Calidi Biotherapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $-54.14. At the end of 2025 the company had an EPS of $-95.20, an increase over its 2024 EPS of $-571.20.
EPS history for Calidi Biotherapeutics, Inc. from 2020 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-54.14 | -43.13% |
| 2025 | $-95.20 | -83.33% |
| 2024 | $-571.20 | -82.80% |
| 2023 | $-3.32K | -42.14% |
| 2022 | $-5.74K | -2,633.90% |
| 2021 | $226.56 | -636.36% |
| 2020 | $-42.24 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -128.93% |
US
|
|
| $-7.07 | -86.94% |
US
|
|
| $-5.29 | -90.23% |
AU
|
|
| $12.88 | -123.79% |
BE
|
|
| $21.56 | -139.82% |
NL
|
Questions about Calidi Biotherapeutics, Inc.'s earnings per share (EPS)
What is Calidi Biotherapeutics, Inc.'s earnings per share (EPS)?
Calidi Biotherapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $-54.14, as of Jun 2026.
What was Calidi Biotherapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Calidi Biotherapeutics, Inc.'s earnings per share (EPS) was $-95.20, compared with $-571.20 in 2024.
How has Calidi Biotherapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Calidi Biotherapeutics, Inc.'s earnings per share (EPS) was highest in 2021 ($226.56) and lowest in 2022 ($-5.74K).
How does Calidi Biotherapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Calidi Biotherapeutics, Inc.'s earnings per share (EPS) ($-54.14) is lower than that of all 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.